Filing Analysis
Lantern Pharma Inc. filed an 8-K to furnish a presentation used on June 1, 2026, regarding the Harmonic™ Phase 2 clinical trial for its product candidate LP-300.
📋 Key Facts
- The filing date is June 1, 2026.
- The company provided a presentation (Exhibit 99.1) concerning the Harmonic™ Phase 2 clinical trial.
- The subject of the trial is the product candidate LP-300.
Lantern Pharma Inc. announced its financial results for the first quarter ended March 31, 2026. The announcement was made via a press release furnished as an exhibit to the filing.
📋 Key Facts
- The report was filed on May 15, 2026, regarding financial results for the quarter ended March 31, 2026.
- The filing was made under Item 2.02 (Results of Operations and Financial Condition).
- The financial information was furnished and not deemed 'filed' for purposes of Section 18 of the Exchange Act.
Lantern Pharma raised $4.4 million through a registered direct offering and concurrent private placement of warrants. Additionally, the company announced plans to spin off its AI platform, withZeta.ai, into an independent business entity to potentially realize separate valuation multiples.
🚩 Red Flags
- 100% warrant coverage (2,135,923 warrants issued alongside 2,135,923 shares/pre-funded warrants) which is highly dilutive.
- Two-year restriction on 'Variable Rate Transactions', which may limit future financing flexibility.
- The offering price of $2.06 and warrant exercise price of $2.27 suggest significant downward pressure on the stock price relative to historical levels.
📋 Key Facts
- Issued 1,454,175 shares of common stock and 681,748 pre-funded warrants at an offering price of $2.06 per unit.
- Concurrent private placement of 2,135,923 purchase warrants with an exercise price of $2.27 per share.
- Total gross proceeds of approximately $4.4 million before fees and expenses.
- Announced the planned creation of an independent entity for the 'withZeta.ai' platform and related technologies.
- Suspended the existing At-The-Market (ATM) sales agreement with ThinkEquity LLC as of May 12, 2026.
- Investors in this round received a right to participate in up to 30% of future equity financings of the AI subsidiary.
Lantern Pharma Inc. conducted a live demonstration and presentation of its 'withZeta.ai' platform, a multi-agentic AI co-scientist designed for rare cancer drug discovery and clinical trial design. The presentation detailed the platform's commercial architecture, revenue strategy, and growth roadmap.
🚩 Red Flags
- The company notes a risk that they may not be able to secure sufficient future funding to support the withZeta.ai platform.
📋 Key Facts
- The demonstration occurred on April 9, 2026, focusing on the withZeta.ai platform.
- The platform is intended to assist in rare cancer drug discovery, development, and clinical trial design.
- The company's near-term revenue strategy for the platform includes software licensing and subscription models.
- A replay of the demonstration was made available via a Zoom recording link.
- The filing includes Exhibit 99.1, which is the presentation used during the demonstration.
Lantern Pharma Inc. announced its financial and operating results for the fiscal year and fourth quarter ended December 31, 2025. The filing includes a press release and a presentation for a scheduled conference call and live webinar to discuss these results.
📋 Key Facts
- Financial results for the fiscal year and fourth quarter ended December 31, 2025, were announced on March 30, 2026.
- The company furnished a press release as Exhibit 99.1 under Item 2.02.
- A presentation for a conference call and live webinar was furnished as Exhibit 99.2 under Item 7.01.
- The filing was signed by David R. Margrave, Chief Financial Officer.